Summit Therapeutics Inc. vs CRISPR Therapeutics AG: SG&A Expense Trends

SG&A Expense Trends: A Tale of Two Biotech Innovators

In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two pioneering companies: CRISPR Therapeutics AG and Summit Therapeutics Inc., from 2014 to 2023.

CRISPR Therapeutics AG, a leader in gene-editing technology, has seen its SG&A expenses grow by approximately 1,400% over the decade, peaking in 2021 with a slight dip in 2023. This reflects their aggressive expansion and investment in cutting-edge research. Meanwhile, Summit Therapeutics Inc., known for its innovative antibiotic solutions, experienced a more modest increase of around 315% in SG&A expenses, indicating a steady growth trajectory.

These trends highlight the contrasting strategies of these biotech giants, with CRISPR focusing on rapid expansion and Summit maintaining a steady course. Investors should consider these financial patterns when evaluating potential opportunities in the biotech sector.